Amicus Therapeutics Inc., of Cranbury, N.J., reported net revenue of $7.2 million, primarily from commercial sales of its Fabry disease therapy Galafold (migalastat), which launched in May 2016. Net loss for the quarter was $48.1 million, or 34 cents per share, compared to a net loss of $51.1 million, or 40 cents per share, for the second quarter 2016. The company ended the quarter with about $227.2 million in cash and cash equivalents. Its shares (NASDAQ:FOLD) gained 67 cents to close at $13.90.